Atiratecan

Atiratecan (TP300) is a proagent of camptothecin analog CH0793076 (HY-107096) . Atiratecan does not inhibit acetylcholinesterase (AChE) activities. Atiratecan shows antitumor activity against both breast cancer resistance protein (BCRP) -positive and -negative xenografts in mouse xenograft models[1].

Product Specifications

CAS Number

[867063-97-6]

Product Name Alternative

TP300

UNSPSC

12352005

Hazard Statement

H301

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/atiratecan.html

Solubility

10 mM in DMSO

Smiles

O=C(O[C@](C(C=C12)=C(CO3)C(N1CC(C2=N4)=C5N(CCCCC)C=NC6=C5C4=CC=C6)=O)(CC)C3=O)CN(C(CN)=O)C

Molecular Formula

C31H34N6O6

Molecular Weight

586.64

Precautions

P264-P270-P330-P405-P501

References & Citations

[1]Endo M, et al. A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancerresistance protein-expressing tumor xenografts. Cancer Chemother Pharmacol. 2010 Jan;65 (2) :363-71.